Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview

Insight Molecular Diagnostics

08/08/2026 24:22

Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to  show a fall in quarterly revenue when it reports  results on August 10 for the period ending June 30 2026
The Nashville Tennessee-based  company is expected to report a 15.5% decrease in revenue to $437.5 thousand from $518 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Insight Molecular Diagnostics Inc is for a loss of 24 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $9.00, about 86.3% above its last closing price of $4.83
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.27
-0.26
-0.12
Beat
54.1
Dec. 31 2026
-0.24
-0.72
Missed
-203.5
Sep. 30 2025
-0.22
-0.21
-0.34
Missed
-62.1​
Jun. 30 2025
-0.23
-0.23
-0.30
Missed
-30.4
​​Mar. 31 2025
-0.24
-0.24
-0.26
Missed
-9.9
Dec. 31 2024
-0.44
-0.43
-1.93
Missed
-351.6​
Sep. 30 2024
-0.44
-0.44
-0.98
Missed
-124.8
Jun. 30 2024
-0.55
-0.56
-0.36
Beat
35.6
This summary was machine generated August 7 at 23:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)